Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells

被引:10
|
作者
Betriu, Nausika [1 ]
Andreeva, Anna [1 ]
Semino, Carlos E. [1 ]
机构
[1] Ramon Llull Univ, IQS Sch Engn, Dept Bioengn, Tissue Engn Res Lab, Barcelona 08017, Spain
关键词
EGFR; trafficking; degradation; self-assembling peptides; 3D culture; pancreatic ductal adenocarcinoma; PDAC; drug resistance; EPIDERMAL-GROWTH-FACTOR; INHIBITOR ERLOTINIB; CANCER; AUTOPHAGY; ENDOCYTOSIS; RESISTANCE; TISSUE; TRAFFICKING; MECHANISMS; RECEPTORS;
D O I
10.3390/cancers13184504
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The EGFR is a tyrosine kinase receptor that responds to different stresses such as UV irradiation, hypoxia and drug treatment by internalizing into endosomal compartments. Receptor trafficking and degradation due to tyrosine kinase inhibitors has been widely studied in two- dimensional (2D) cell culture systems, but little is known about how cells respond to these types of drugs in more physiologically relevant models such as three-dimensional (3D) cultures, whose nanostructured properties allow cells to grow, proliferate, migrate and extend cellular processes in their 3D space. In this study, we show that EGFR suffers degradation in response to erlotinib treatment in 3D-cultured cancer cells but not in classic 2D culture systems, demonstrating that dimensionality strongly affects cell drug response. This 3D model may pave the way for the development of more physiological culture platforms to obtain mechanistic insights into how cells respond to chemotherapy. The epithelial growth factor receptor (EGFR) is a tyrosine kinase receptor that participates in many biological processes such as cell proliferation. In addition, EGFR is overexpressed in many epithelial cancers and therefore is a target for cancer therapy. Moreover, EGFR responds to lots of stimuli by internalizing into endosomes from where it can be recycled to the membrane or further sorted into lysosomes where it undergoes degradation. Two-dimensional cell cultures have been classically used to study EGFR trafficking mechanisms in cancer cells. However, it has been widely demonstrated that in 2D cultures cells are exposed to a non-physiological environment as compared to 3D cultures that provide the normal cellular conformation, matrix dimensionality and stiffness, as well as molecular gradients. Therefore, the microenvironment of solid tumors is better recreated in 3D culture models, and this is why they are becoming a more physiological alternative to study cancer physiology. Here, we develop a new model of EGFR internalization and degradation upon erlotinib treatment in pancreatic ductal adenocarcinoma (PDAC) cells cultured in a 3D self-assembling peptide scaffold. In this work, we show that treatment with the tyrosine kinase inhibitor erlotinib promotes EGFR degradation in 3D cultures of PDAC cell lines but not in 2D cultures. We also show that this receptor degradation does not occur in normal fibroblast cells, regardless of culture dimensionality. In conclusion, we demonstrate not only that erlotinib has a distinct effect on tumor and normal cells but also that pancreatic ductal adenocarcinoma cells respond differently to drug treatment when cultured in a 3D microenvironment. This study highlights the importance of culture systems that can more accurately mimic the in vivo tumor physiology.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Polychromatic light-induced osteogenic activity in 2D and 3D cultures
    Nazife Ülker
    Anıl S. Çakmak
    Arlin S. Kiremitçi
    Menemşe Gümüşderelioğlu
    Lasers in Medical Science, 2016, 31 : 1665 - 1674
  • [22] Effects of anticancer drugs on colorectal carcinoma cells in 2D and 3D cultures
    Ogawa, Yutaro
    Shinji, Seiichi
    Shichi, Yuuki
    Yamada, Takeshi
    Uehara, Kay
    Matsuda, Akihisa
    Yokoyama, Yasuyuki
    Takahashi, Goro
    Iwai, Takuma
    Takeda, Kohki
    Kuriyama, Sho
    Gomi, Fujiya
    Fujiwara, Masakazu
    Ishiwata, Toshiyuki
    Yoshida, Hiroshi
    CANCER SCIENCE, 2025, 116 : 1013 - 1013
  • [23] Use of 2D and 3D cell cultures in dermatology
    Zeitvogel, J.
    Werfel, T.
    HAUTARZT, 2020, 71 (02): : 91 - 100
  • [24] Investigating differential expression of Palladin isoform 3 in 2D and 3D pancreatic cancer cell cultures
    Biswas, Sonali
    Bush, Jason A.
    CANCER RESEARCH, 2024, 84 (06)
  • [25] Development of 3D models of pancreatic ductal adenocarcinoma via tissue engineering
    Danti, S.
    Ricci, C.
    Moscato, S.
    Mota, C.
    D'alessandro, D.
    Bronte, V.
    Funel, N.
    Moroni, L.
    JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2014, 8 : 313 - 314
  • [26] Ex-Vivo 3D Cellular Models of Pancreatic Ductal Adenocarcinoma
    Acimovic, Ivana
    Gabrielova, Viktorie
    Martinkova, Stanislava
    Eid, Michal
    Vlazny, Jakub
    Moravcik, Petr
    Hlavsa, Jan
    Moran, Lukas
    Cakmakci, Riza Can
    Stano, Peter
    Prochazka, Vladimir
    Kala, Zdenek
    Trnka, Jan
    Vanhara, Petr
    PANCREAS, 2025, 54 (01) : e57 - e71
  • [27] A 3D Bio-Printed-Based Model for Pancreatic Ductal Adenocarcinoma
    Godier, Claire
    Baka, Zakaria
    Lamy, Laureline
    Gribova, Varvara
    Marchal, Philippe
    Lavalle, Philippe
    Gaffet, Eric
    Bezdetnaya, Lina
    Alem, Halima
    DISEASES, 2024, 12 (09)
  • [28] Characterizing 2D and 3D Organoid Cultures Derived From Mouse and Human Pancreatic Specimens
    Szabo, V.
    Varga, A.
    Maleth, J.
    PANCREAS, 2021, 50 (07) : 1101 - 1101
  • [29] Pituitary Lineage Differentiation from Human-Induced Pluripotent Stem Cells in 2D and 3D Cultures
    Zhou, Yu
    Wilson, Robert R. A.
    Udaiyar, Abinav
    McLemore, Jerri
    Sadri-Ardekani, Hooman
    Criswell, Tracy
    STEM CELLS AND DEVELOPMENT, 2022, 31 (9-10) : 239 - 249
  • [30] Innovations in perovskite solar cells: a journey through 2D, 3D, and 2D/3D heterojunctions
    Sehar, Anum
    Nasir, Fariha
    Farhan, Ahmad
    Akram, Samiullah
    Qayyum, Wajeeha
    Zafar, Kainat
    Ali, Syed Kashif
    Qamar, Muhammad Azam
    REVIEWS IN INORGANIC CHEMISTRY, 2024,